EUCTR2007-005687-27-ESActive, not recruitingPhase 1
Estudio aleatorizado, en doble ciego y controlado con placebo, de la eficacia y la seguridad de TAK-242 frente al placebo en sujetos con insuficiencia cardiovascular y respiratoria inducida por sepsisA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety ofTAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory Failure
Takeda Global Research & Development Centre (Europe), Ltd.0 sites2,500 target enrollmentStarted: March 8, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 2,500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. The subject is aged 18 years or older.
- •2. The subject has a suspected or proven bacterial or fungal infection for which he or she is receiving parenteral antimicrobial therapy.
- •3. The subject has developed at least 3 of the 4 following SIRS criteria within 36 hours prior to start of study drug administration:
- •a. A temperature from any site >38°C (>100.4°F) or a core temperature (ie, rectal or central) <36°C (<96.8°F).
- •b. Heart rate of >90 beats per minute. If subject has a known medical condition (eg, heart block) or is receiving treatment (eg, beta blocker) that would prevent tachycardia, only 2 of the remaining 3 criteria for SIRS must be met.
- •c. Respiratory rate of >20 breaths/min or arterial partial pressure of carbon dioxide of <32 mm Hg or mechanical ventilation for an acute process.
- •d. A total white blood cell (WBC) absolute count >12,000 cells/mm3 or <4,000 cells/mm3; or a WBC differential count showing >10% immature (band) forms.
- •4. The subject has septic shock diagnosed within 36 hours prior to study drug administration. Septic shock is defined as hypotension with a persistent requirement for vasopressors to maintain systolic blood pressure >90 mm Hg or mean arterial pressure (MAP) >60 mm Hg, despite adequate fluid resuscitation (eg, >20 mL/kg) or documentation of a central venous pressure >8 mm Hg or a pulmonary artery occlusion pressure >12 mm Hg. Vasopressor is defined as >5 µg/kg/min dopamine or any dose of norepinephrine, epinephrine, vasopressin, or phenylephrine.
- •5. The subject has developed respiratory failure within 36 hours prior to study drug
- •administration. Respiratory failure is defined as a ratio of partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FIO2) of <200 while receiving positive pressure ventilation via tracheal tube.
- •6. The central trial coordinating center, VCC, has approved subject eligibility.
- •7. The subject or the subjects legally authorized representative has provided written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. The subject has received any investigational compound within 30 days (or 5 half-lives of the drug, whichever is longer) prior to the initiation of the study drug infusion or is participating in another investigational study, not including investigational compound, without prior approval from the VCC/sponsor.
- •2. The subject is a study site employee, or is an immediate family member (ie, spouse, parent, child, sibling) of a study site employee, involved in conduct of this study.
- •3. A female subject who is pregnant or nursing.
- •4. The subject is currently receiving any immunosuppressive therapy (excluding glucocorticoids) such as methotrexate, azathioprine, anti tumor necrosis factor a (TNF-a), or a cancer related chemotherapeutic agent.
- •5. The subject has a known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- •6. The subject has a methemoglobin level of =5% at pretreatment period or has a known history of methemoglobinemia.
- •7. The subject is moribund and death is considered imminent.
- •8. Prior to the onset of sepsis, the subject would not otherwise have been expected to survive 28 days or to complete a functional recovery due to a pre-existing unstable medical condition (eg, a recent acute cerebral hemorrhage or infarct, a recent acute unstable myocardial infarction, severe traumatic injury).
- •9. The subject has a poorly controlled or metastatic neoplasm.
- •10. The subject, family, or physician is not committed to full aggressive management or the presence of an unstable medical condition makes the receipt of full aggressive management support unlikely in the view of the coordinating center. The presence of a do not resuscitate order does not automatically exclude participation.
- •11. The subject has severe end stage chronic respiratory failure or lung disease that significantly impairs physical functioning equivalent to that of New York Heart Association (NYHA) functional classification III or IV.
- •12. The subject has a documented history of moderate to severe chronic heart failure as defined by NYHA functional classification III or IV.
- •13. The subject has received electrocardioversion for a pulse-less rhythm or chest compressions during their current hospitalization.
- •14. The subject is known to be immunocompromised such as subjects with human immunodeficiency virus and a CD4 count <50 mm3, primary immune deficiency or chronic lymphocytic leukemia.
- •15. The subject has chronic end stage hepatic failure or significant sequelae of chronic hepatic failure (eg, esophageal varices, jaundice, chronic ascites) or Child-Pugh hepatic impairment Classification C.
- •16. The subject is in a chronic vegetative state or has a similar long-term neurological impairment, where continued aggressive care would be unlikely.
- •17. The subject has acute third degree burns involving more than 30% of body surface area within 120 hours of first qualifying organ failure.
- •18. The subject has known hypersensitivity to sulphonamides.
- •19. The subject has known hypersensitivity to components of TAK-242; for example, is allergic to eggs, egg products, or soybeans.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Estudio aleatorizado, en doble ciego y controlado con placebo de una dosis fija de metilnaltrexona subcutánea en adultos con enfermedad avanzada y estreñimiento inducido por opiáceos: eficacia, seguridad y cuestionarios de salud adicionalesA Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health OutcomesPacientes con enfermedad avanzada y estreñimiento inducido por opiáceosOpioid-induced constipation in subjects with advanced illnessMedDRA version: 9.1Level: LLTClassification code 10010774Term: ConstipationEUCTR2007-000854-30-ESWyeth Research Division of Wyeth Pharmaceuticals Inc., Global Medical Affairs500
Active, not recruiting
Phase 1
Estudio aleatorizado, doble ciego y controlado con placebo con 3 grupos paralelos para evaluar la eficacia y la seguridad de linagliptina en dosis de 2,5 mg dos veces al día frente a 5 mg una vez al día durante 12 semanas como tratamiento adyuvante a un régimen de metformina dos veces al día en pacientes con diabetes mellitus tipo 2 y un control glucémico insuficienteA randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of maximal metformin therapy in patients with type 2 diabetes mellitus and insufficient glycemic controlDiabetes tipo 2Type 2 diabetesMedDRA version: 12.0Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2009-013549-27-ESBoehringer Ingelheim España, S.A.451
Active, not recruiting
Not Applicable
Estudio aleatorizado, doble ciego y controlado con placebo de RAD001 en el tratamiento del angiomiolipoma en pacientes con Complejo de Esclerosis Tuberosa (CET) o linfangioleiomiomatosis esporádica (LAM)EUCTR2008-002113-48-ESovartis Farmacéutica, S.A.99
Active, not recruiting
Phase 1
Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de fesoterodina, como tratamiento añadido, en varones con síntomas persistentes de vejiga hiperactiva que reciben monoterapia con un alfabloqueante para los síntomas del tracto urinario inferior”A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TOEVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE AS ANADD-ON THERAPY IN MEN WITH PERSISTENT OVERACTIVE BLADDERSYMPTOMS UNDER MONOTHERAPY OF ALPHA BLOCKER FOR LOWERURINARY TRACT SYMPTOMSEUCTR2007-004555-11-ESPfizer, S.A.900
Active, not recruiting
Phase 1
n estudio para evaluar la potencia, calidad de vida, efectos secundarios ytolerabilidad del tratamiento a largo plazo (24 semanas) con prucaloprida enpacientes con edad = 18 años con estreñimiento crónico.Chronic constipationEstreñimiento crónicoMedDRA version: 14.0Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-000670-62-ESShire-Movetis NV340